← Back to Search

Corticosteroid

Mometasone for Sickle Cell Disease (IMPROVE2 Trial)

Phase 2

Waitlist Available

Led By Jeffrey Glassberg, MD

Research Sponsored by Jeffrey Glassberg

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and one year

Awards & highlights

IMPROVE2 Trial Summary

This trial will test if inhaled mometasone reduces symptoms of episodic cough or wheeze in people with Sickle Cell Disease.

Eligible Conditions

Sickle Cell Disease

IMPROVE2 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and one year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and one year

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Soluble Vascular Cell Adhesion Molecule (sVCAM) level

Secondary outcome measures

6-Minute Walk Test

Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) survey

Bilirubin (Direct and Indirect) level

+27 more

IMPROVE2 Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: MometasoneActive Control1 Intervention

Inhaled Mometasone Furoate 220 mcg DPI

Group II: PlaceboPlacebo Group1 Intervention

Once daily inhaled placebo

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Jeffrey GlassbergLead Sponsor

1 Previous Clinical Trials

54 Total Patients Enrolled

National Heart, Lung, and Blood Institute (NHLBI)NIH

3,837 Previous Clinical Trials

47,851,514 Total Patients Enrolled

Jeffrey Glassberg, MDPrincipal Investigator - Icahn School of Medicine at Mount Sinai

The Mount Sinai Hospital

Medical School - Washington University, St. Louis, Doctor of Medicine

Bellevue Hospital, Residency in Emergency Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies available for participation in this research project?

"As recorded on clinicaltrials.gov, this research endeavour is not currently searching for participants. It was initially announced on November 29th 2018 and most recently modified on October 11th 2022. However, there are 198 other medical studies actively recruiting now."

Answered by AI

What is the aggregate amount of people taking part in this trial?

"As of now, this clinical trial is not accepting new patients. First posted on November 29th 2018 and last edited October 11th 2022, other medical research projects may be more suitable for those searching to participate in a study; 197 trials are currently recruiting anemic or sickle cell patients while 1 seeks Mometasone participants."

Answered by AI

What conditions is Mometasone typically employed to alleviate?

"Mometasone is an effective therapy for managing the symptoms of asthma, sinusitis, and allergic rhinitis."

Answered by AI

Is Mometasone a risk factor for adverse health effects?

"Our team at Power gave Mometasone a rating of 2, since Phase 2 trials have produced evidence for its safety but not efficacy."

Answered by AI

What past experiments have been conducted that relate to Mometasone?

"Presently, there exists one clinical trial exploring the efficacy of mometasone. Unfortunately, none of these studies have reached phase 3 yet. Despite this setback, two different sites in New york City are still conducting research on it."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2

Jeffrey Glassberg 2018. "Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03758950.